Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Platelet Aggregation Inhibitors | 89 | 2022 | 2751 | 6.970 |
Why?
|
Ticlopidine | 56 | 2017 | 730 | 6.540 |
Why?
|
Thiophenes | 43 | 2015 | 569 | 5.810 |
Why?
|
Glucosides | 27 | 2024 | 512 | 5.610 |
Why?
|
Acute Coronary Syndrome | 69 | 2023 | 2191 | 4.860 |
Why?
|
Benzhydryl Compounds | 30 | 2024 | 916 | 4.840 |
Why?
|
Myocardial Infarction | 126 | 2024 | 11454 | 4.740 |
Why?
|
Piperazines | 42 | 2015 | 2519 | 3.730 |
Why?
|
Angioplasty, Balloon, Coronary | 38 | 2013 | 1731 | 3.180 |
Why?
|
Diabetes Mellitus, Type 2 | 49 | 2024 | 12144 | 3.160 |
Why?
|
Cardiovascular Diseases | 53 | 2024 | 15499 | 1.970 |
Why?
|
Anticholesteremic Agents | 21 | 2023 | 967 | 1.810 |
Why?
|
Platelet Activation | 9 | 2016 | 645 | 1.790 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 32 | 2024 | 3244 | 1.780 |
Why?
|
Heart Failure | 28 | 2024 | 11672 | 1.760 |
Why?
|
Thrombolytic Therapy | 22 | 2018 | 2062 | 1.720 |
Why?
|
Angina, Unstable | 16 | 2019 | 888 | 1.710 |
Why?
|
Pyridines | 27 | 2022 | 2870 | 1.550 |
Why?
|
Purinergic P2 Receptor Antagonists | 9 | 2011 | 67 | 1.500 |
Why?
|
Cholesterol, LDL | 20 | 2023 | 2381 | 1.360 |
Why?
|
Platelet Function Tests | 6 | 2008 | 271 | 1.180 |
Why?
|
Blood Platelets | 11 | 2011 | 2481 | 1.120 |
Why?
|
Hemorrhage | 40 | 2022 | 3425 | 1.110 |
Why?
|
Thrombosis | 19 | 2022 | 2942 | 1.100 |
Why?
|
Registries | 31 | 2020 | 8223 | 1.080 |
Why?
|
Purinergic P2Y Receptor Antagonists | 14 | 2020 | 284 | 1.080 |
Why?
|
Aspirin | 28 | 2020 | 3134 | 1.060 |
Why?
|
Double-Blind Method | 62 | 2024 | 12329 | 1.050 |
Why?
|
Cardiovascular System | 4 | 2023 | 835 | 1.040 |
Why?
|
Treatment Outcome | 107 | 2024 | 64645 | 1.000 |
Why?
|
Electrocardiography | 27 | 2018 | 6382 | 1.000 |
Why?
|
Stroke | 35 | 2023 | 9749 | 0.970 |
Why?
|
Drug Resistance | 8 | 2008 | 1597 | 0.960 |
Why?
|
Cardiovascular Agents | 2 | 2022 | 840 | 0.940 |
Why?
|
Imines | 3 | 2012 | 27 | 0.890 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 90 | 0.850 |
Why?
|
Drug Therapy, Combination | 35 | 2018 | 6309 | 0.850 |
Why?
|
Fibrinolytic Agents | 14 | 2017 | 2082 | 0.830 |
Why?
|
Aged | 161 | 2024 | 169179 | 0.820 |
Why?
|
Stents | 14 | 2016 | 3179 | 0.760 |
Why?
|
Adenosine | 6 | 2016 | 805 | 0.760 |
Why?
|
Heptanoic Acids | 7 | 2011 | 344 | 0.750 |
Why?
|
Pravastatin | 7 | 2011 | 392 | 0.750 |
Why?
|
Middle Aged | 168 | 2024 | 220774 | 0.750 |
Why?
|
Simvastatin | 8 | 2017 | 346 | 0.750 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2024 | 10203 | 0.710 |
Why?
|
Heparin | 11 | 2021 | 1633 | 0.710 |
Why?
|
Glomerular Filtration Rate | 10 | 2024 | 2176 | 0.700 |
Why?
|
Humans | 272 | 2024 | 761326 | 0.700 |
Why?
|
Anticoagulants | 18 | 2022 | 4813 | 0.690 |
Why?
|
Benzazepines | 6 | 2019 | 310 | 0.670 |
Why?
|
Male | 189 | 2024 | 360621 | 0.670 |
Why?
|
Atrial Fibrillation | 10 | 2022 | 5127 | 0.660 |
Why?
|
Anti-Obesity Agents | 4 | 2024 | 227 | 0.660 |
Why?
|
Coronary Disease | 14 | 2017 | 5919 | 0.650 |
Why?
|
Hypercholesterolemia | 6 | 2022 | 1142 | 0.640 |
Why?
|
Female | 189 | 2024 | 392485 | 0.640 |
Why?
|
Coronary Artery Disease | 14 | 2021 | 6392 | 0.610 |
Why?
|
Hypoglycemic Agents | 14 | 2024 | 3082 | 0.610 |
Why?
|
Albuminuria | 2 | 2021 | 657 | 0.610 |
Why?
|
Risk Assessment | 39 | 2024 | 23981 | 0.600 |
Why?
|
Receptors, Thrombin | 4 | 2014 | 130 | 0.600 |
Why?
|
Symporters | 1 | 2020 | 363 | 0.600 |
Why?
|
Hirudins | 3 | 2017 | 179 | 0.590 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 11 | 2018 | 577 | 0.590 |
Why?
|
Diabetic Angiopathies | 4 | 2018 | 804 | 0.570 |
Why?
|
Acute Kidney Injury | 3 | 2022 | 1926 | 0.560 |
Why?
|
Creatinine | 3 | 2021 | 1899 | 0.560 |
Why?
|
Dose-Response Relationship, Drug | 26 | 2018 | 10764 | 0.560 |
Why?
|
Cholesterol, VLDL | 2 | 2024 | 70 | 0.560 |
Why?
|
Platelet Aggregation | 8 | 2011 | 773 | 0.560 |
Why?
|
Pyrroles | 7 | 2011 | 1126 | 0.560 |
Why?
|
Drug-Eluting Stents | 6 | 2016 | 680 | 0.550 |
Why?
|
Tyrosine | 7 | 2016 | 1438 | 0.540 |
Why?
|
Antithrombins | 2 | 2017 | 294 | 0.540 |
Why?
|
Coronary Angiography | 19 | 2020 | 4472 | 0.540 |
Why?
|
Obesity | 12 | 2024 | 12934 | 0.510 |
Why?
|
Patient Participation | 2 | 2015 | 1443 | 0.500 |
Why?
|
Hospitalization | 19 | 2023 | 10715 | 0.490 |
Why?
|
Coronary Thrombosis | 4 | 2014 | 440 | 0.480 |
Why?
|
Brain Ischemia | 6 | 2020 | 3048 | 0.480 |
Why?
|
Oxazolidinones | 3 | 2022 | 98 | 0.470 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2024 | 2241 | 0.460 |
Why?
|
Risk Factors | 63 | 2024 | 74152 | 0.460 |
Why?
|
Thiazoles | 7 | 2022 | 1516 | 0.450 |
Why?
|
Cyclic N-Oxides | 5 | 2021 | 72 | 0.450 |
Why?
|
Antibodies, Monoclonal | 9 | 2022 | 9180 | 0.450 |
Why?
|
Atherosclerosis | 11 | 2023 | 3413 | 0.430 |
Why?
|
Peptide Fragments | 7 | 2024 | 5114 | 0.430 |
Why?
|
Diabetic Nephropathies | 4 | 2022 | 973 | 0.420 |
Why?
|
CD40 Ligand | 2 | 2012 | 526 | 0.420 |
Why?
|
Hypolipidemic Agents | 5 | 2018 | 609 | 0.410 |
Why?
|
Tissue Plasminogen Activator | 2 | 2017 | 1164 | 0.400 |
Why?
|
Time Factors | 40 | 2024 | 39974 | 0.400 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2012 | 127 | 0.390 |
Why?
|
Warfarin | 7 | 2022 | 1483 | 0.390 |
Why?
|
Natriuretic Peptide, Brain | 6 | 2024 | 1723 | 0.380 |
Why?
|
Thrombocytopenia | 2 | 2017 | 1179 | 0.380 |
Why?
|
Cause of Death | 12 | 2024 | 3685 | 0.370 |
Why?
|
Hospital Mortality | 12 | 2020 | 5291 | 0.370 |
Why?
|
Follow-Up Studies | 35 | 2020 | 39108 | 0.360 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.360 |
Why?
|
Endpoint Determination | 6 | 2018 | 590 | 0.350 |
Why?
|
Overweight | 6 | 2024 | 2412 | 0.350 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7824 | 0.340 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 5 | 2010 | 244 | 0.340 |
Why?
|
Drug Administration Schedule | 14 | 2019 | 4850 | 0.340 |
Why?
|
Clinical Trials as Topic | 10 | 2019 | 7999 | 0.320 |
Why?
|
Myocardial Revascularization | 8 | 2018 | 792 | 0.320 |
Why?
|
Hyperlipidemias | 3 | 2023 | 771 | 0.320 |
Why?
|
Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 31 | 0.310 |
Why?
|
Chest Pain | 5 | 2015 | 1090 | 0.310 |
Why?
|
Kaplan-Meier Estimate | 15 | 2017 | 6473 | 0.310 |
Why?
|
Appetite Depressants | 2 | 2019 | 108 | 0.300 |
Why?
|
Enoxaparin | 5 | 2009 | 391 | 0.300 |
Why?
|
Quinolines | 2 | 2023 | 764 | 0.290 |
Why?
|
Myocardial Ischemia | 8 | 2018 | 2110 | 0.290 |
Why?
|
Death, Sudden, Cardiac | 8 | 2018 | 1555 | 0.290 |
Why?
|
Coronary Artery Bypass | 7 | 2018 | 2189 | 0.290 |
Why?
|
Lactones | 3 | 2014 | 317 | 0.290 |
Why?
|
Fluorobenzenes | 1 | 2009 | 179 | 0.290 |
Why?
|
Guideline Adherence | 9 | 2020 | 2221 | 0.280 |
Why?
|
Patient Discharge | 6 | 2021 | 3438 | 0.280 |
Why?
|
Kidney Diseases | 5 | 2020 | 2093 | 0.280 |
Why?
|
Cholesterol | 5 | 2024 | 2902 | 0.280 |
Why?
|
Lipoproteins, LDL | 3 | 2006 | 642 | 0.270 |
Why?
|
Stroke Volume | 3 | 2019 | 5497 | 0.270 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3878 | 0.260 |
Why?
|
Research Design | 7 | 2018 | 6178 | 0.250 |
Why?
|
Incidence | 21 | 2024 | 21336 | 0.250 |
Why?
|
Proton Pump Inhibitors | 2 | 2013 | 531 | 0.250 |
Why?
|
Embolism | 2 | 2022 | 400 | 0.250 |
Why?
|
Clinical Trials, Phase III as Topic | 5 | 2020 | 857 | 0.250 |
Why?
|
Creatine Kinase, MB Form | 6 | 2014 | 202 | 0.250 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2006 | 168 | 0.250 |
Why?
|
Death | 2 | 2020 | 676 | 0.240 |
Why?
|
Triglycerides | 5 | 2024 | 2458 | 0.240 |
Why?
|
Insulin | 4 | 2023 | 6595 | 0.240 |
Why?
|
Health Status Disparities | 1 | 2016 | 1852 | 0.240 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 3 | 2019 | 311 | 0.230 |
Why?
|
Secondary Prevention | 13 | 2019 | 1474 | 0.230 |
Why?
|
Oligonucleotides, Antisense | 2 | 2024 | 461 | 0.230 |
Why?
|
Practice Guidelines as Topic | 16 | 2020 | 7389 | 0.230 |
Why?
|
Multicenter Studies as Topic | 5 | 2018 | 1703 | 0.230 |
Why?
|
Myocardial Reperfusion | 4 | 2014 | 338 | 0.230 |
Why?
|
Pulmonary Embolism | 1 | 2017 | 2566 | 0.230 |
Why?
|
Weight Loss | 5 | 2024 | 2683 | 0.230 |
Why?
|
Glucose | 5 | 2022 | 4345 | 0.220 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 153 | 0.210 |
Why?
|
Aged, 80 and over | 26 | 2021 | 58946 | 0.210 |
Why?
|
Recurrence | 12 | 2021 | 8470 | 0.210 |
Why?
|
Troponin | 3 | 2020 | 501 | 0.210 |
Why?
|
Hyperglycemia | 1 | 2011 | 1375 | 0.210 |
Why?
|
C-Reactive Protein | 8 | 2016 | 3824 | 0.200 |
Why?
|
Drug Monitoring | 2 | 2018 | 961 | 0.200 |
Why?
|
Coronary Stenosis | 3 | 2014 | 794 | 0.200 |
Why?
|
Blood Coagulation | 2 | 2018 | 1154 | 0.190 |
Why?
|
Sodium | 3 | 2022 | 1588 | 0.190 |
Why?
|
Receptor, PAR-1 | 2 | 2012 | 109 | 0.190 |
Why?
|
Blood Glucose | 2 | 2017 | 6389 | 0.190 |
Why?
|
Heart | 1 | 2014 | 4405 | 0.190 |
Why?
|
No-Reflow Phenomenon | 1 | 2021 | 16 | 0.190 |
Why?
|
Hypokalemia | 1 | 2022 | 153 | 0.180 |
Why?
|
Peripheral Arterial Disease | 3 | 2022 | 1272 | 0.180 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 69 | 0.180 |
Why?
|
Ventricular Function | 4 | 2006 | 406 | 0.180 |
Why?
|
Combined Modality Therapy | 8 | 2014 | 8526 | 0.180 |
Why?
|
Healthcare Disparities | 1 | 2016 | 3357 | 0.180 |
Why?
|
Administration, Oral | 4 | 2018 | 4013 | 0.180 |
Why?
|
Eye Hemorrhage | 1 | 2020 | 19 | 0.180 |
Why?
|
Acute Disease | 9 | 2014 | 7238 | 0.170 |
Why?
|
Sex Characteristics | 3 | 2021 | 2637 | 0.170 |
Why?
|
Primary Prevention | 3 | 2021 | 1186 | 0.170 |
Why?
|
Hyperkalemia | 1 | 2022 | 233 | 0.170 |
Why?
|
Diuretics | 1 | 2022 | 610 | 0.160 |
Why?
|
Sulfonamides | 1 | 2009 | 1976 | 0.160 |
Why?
|
Morpholines | 2 | 2013 | 581 | 0.160 |
Why?
|
United States | 27 | 2020 | 72317 | 0.160 |
Why?
|
Whole Blood Coagulation Time | 1 | 2018 | 30 | 0.160 |
Why?
|
Models, Biological | 2 | 2012 | 9468 | 0.160 |
Why?
|
Appetite Regulation | 1 | 2019 | 84 | 0.160 |
Why?
|
Life Expectancy | 2 | 2024 | 1242 | 0.150 |
Why?
|
Hospitals | 3 | 2020 | 3878 | 0.150 |
Why?
|
Prodrugs | 3 | 2009 | 261 | 0.150 |
Why?
|
Diuresis | 1 | 2018 | 106 | 0.150 |
Why?
|
Drug Therapy | 1 | 2021 | 503 | 0.150 |
Why?
|
Risk | 10 | 2020 | 9605 | 0.150 |
Why?
|
Decision Support Techniques | 2 | 2019 | 1998 | 0.150 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2022 | 1039 | 0.140 |
Why?
|
Syndrome | 5 | 2008 | 3268 | 0.140 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1722 | 0.140 |
Why?
|
Cholesterol, HDL | 6 | 2022 | 1814 | 0.140 |
Why?
|
Adamantane | 2 | 2019 | 148 | 0.140 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 175 | 0.140 |
Why?
|
Severity of Illness Index | 9 | 2020 | 15835 | 0.140 |
Why?
|
Pyrimidines | 1 | 2009 | 3025 | 0.140 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2017 | 113 | 0.140 |
Why?
|
Infusions, Intravenous | 3 | 2017 | 2217 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 6 | 2017 | 20555 | 0.140 |
Why?
|
Hypoglycemia | 3 | 2019 | 884 | 0.130 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2019 | 396 | 0.130 |
Why?
|
Aryldialkylphosphatase | 1 | 2016 | 64 | 0.130 |
Why?
|
Dipeptides | 2 | 2019 | 391 | 0.130 |
Why?
|
Peptides | 4 | 2016 | 4342 | 0.130 |
Why?
|
Angioplasty | 2 | 2011 | 354 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1517 | 0.130 |
Why?
|
Kidney | 5 | 2023 | 7049 | 0.120 |
Why?
|
Proportional Hazards Models | 10 | 2019 | 12450 | 0.120 |
Why?
|
Extremities | 1 | 2020 | 867 | 0.120 |
Why?
|
Drug Substitution | 1 | 2017 | 289 | 0.120 |
Why?
|
Postoperative Complications | 4 | 2018 | 15647 | 0.120 |
Why?
|
Phentermine | 1 | 2014 | 31 | 0.120 |
Why?
|
Benzaldehydes | 1 | 2014 | 59 | 0.120 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1007 | 0.120 |
Why?
|
Cyclopropanes | 1 | 2016 | 432 | 0.120 |
Why?
|
Recombinant Proteins | 5 | 2017 | 6525 | 0.120 |
Why?
|
Azetidines | 1 | 2015 | 140 | 0.110 |
Why?
|
Patient Selection | 4 | 2019 | 4244 | 0.110 |
Why?
|
Survival Analysis | 8 | 2019 | 10075 | 0.110 |
Why?
|
Adult | 29 | 2024 | 221122 | 0.110 |
Why?
|
Logistic Models | 8 | 2013 | 13251 | 0.110 |
Why?
|
Prospective Studies | 8 | 2020 | 54405 | 0.110 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2008 | 3441 | 0.110 |
Why?
|
Risk Reduction Behavior | 2 | 2019 | 1112 | 0.110 |
Why?
|
Prevalence | 6 | 2021 | 15719 | 0.110 |
Why?
|
Angina Pectoris | 3 | 2007 | 959 | 0.110 |
Why?
|
Sex Factors | 5 | 2021 | 10551 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 809 | 0.110 |
Why?
|
Multivariate Analysis | 5 | 2017 | 12059 | 0.110 |
Why?
|
Disease Progression | 6 | 2023 | 13500 | 0.110 |
Why?
|
Predictive Value of Tests | 9 | 2019 | 15262 | 0.110 |
Why?
|
Fibrinolysis | 2 | 2011 | 332 | 0.110 |
Why?
|
Oximes | 1 | 2014 | 303 | 0.110 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 687 | 0.110 |
Why?
|
Cerebral Infarction | 1 | 2018 | 983 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2022 | 1303 | 0.100 |
Why?
|
Fatal Outcome | 1 | 2017 | 1833 | 0.100 |
Why?
|
Acetanilides | 1 | 2014 | 169 | 0.100 |
Why?
|
Bupropion | 1 | 2014 | 304 | 0.100 |
Why?
|
Receptors, Purinergic P2Y12 | 3 | 2011 | 115 | 0.100 |
Why?
|
Fructose | 1 | 2014 | 288 | 0.100 |
Why?
|
Troponin I | 2 | 2012 | 651 | 0.100 |
Why?
|
Bone Density Conservation Agents | 1 | 2019 | 795 | 0.100 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2016 | 339 | 0.100 |
Why?
|
Troponin T | 2 | 2015 | 779 | 0.100 |
Why?
|
Naltrexone | 1 | 2014 | 317 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 754 | 0.100 |
Why?
|
Myocarditis | 1 | 2019 | 786 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2017 | 908 | 0.100 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2009 | 0.100 |
Why?
|
Meta-Analysis as Topic | 2 | 2006 | 1376 | 0.100 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2016 | 445 | 0.100 |
Why?
|
Intraoperative Care | 1 | 2015 | 766 | 0.090 |
Why?
|
Diabetes Mellitus | 4 | 2017 | 5841 | 0.090 |
Why?
|
Protein Precursors | 2 | 2013 | 1134 | 0.090 |
Why?
|
Polymorphism, Genetic | 3 | 2010 | 4286 | 0.090 |
Why?
|
Eligibility Determination | 1 | 2014 | 421 | 0.090 |
Why?
|
Chi-Square Distribution | 6 | 2012 | 3419 | 0.090 |
Why?
|
Anemia | 1 | 2020 | 1508 | 0.090 |
Why?
|
Cross-Over Studies | 4 | 2011 | 2075 | 0.090 |
Why?
|
Inpatients | 2 | 2012 | 2548 | 0.090 |
Why?
|
Evidence-Based Medicine | 3 | 2014 | 3687 | 0.090 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 694 | 0.090 |
Why?
|
Transportation of Patients | 1 | 2011 | 174 | 0.090 |
Why?
|
Platelet Adhesiveness | 1 | 2010 | 154 | 0.090 |
Why?
|
Metformin | 1 | 2018 | 907 | 0.090 |
Why?
|
International Normalized Ratio | 1 | 2012 | 382 | 0.090 |
Why?
|
Emergency Service, Hospital | 4 | 2013 | 7872 | 0.090 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2019 | 1392 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2015 | 1184 | 0.080 |
Why?
|
Streptokinase | 1 | 2009 | 186 | 0.080 |
Why?
|
Italy | 1 | 2011 | 841 | 0.080 |
Why?
|
Blood Proteins | 1 | 2014 | 1180 | 0.080 |
Why?
|
Blood Pressure | 2 | 2022 | 8485 | 0.080 |
Why?
|
Drug Interactions | 2 | 2013 | 1415 | 0.080 |
Why?
|
Health Services Research | 1 | 2016 | 1811 | 0.080 |
Why?
|
Reproducibility of Results | 7 | 2019 | 20092 | 0.080 |
Why?
|
Prognosis | 12 | 2024 | 29588 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3324 | 0.080 |
Why?
|
Odds Ratio | 8 | 2013 | 9639 | 0.080 |
Why?
|
Lipoproteins | 2 | 2024 | 881 | 0.080 |
Why?
|
Cohort Studies | 9 | 2018 | 41440 | 0.080 |
Why?
|
Drug Combinations | 1 | 2014 | 2048 | 0.080 |
Why?
|
Body Mass Index | 3 | 2024 | 12949 | 0.080 |
Why?
|
Membrane Proteins | 1 | 2005 | 7852 | 0.080 |
Why?
|
Coronary Circulation | 3 | 2014 | 1565 | 0.080 |
Why?
|
Apolipoproteins B | 2 | 2022 | 386 | 0.080 |
Why?
|
Cardiology | 1 | 2019 | 1667 | 0.080 |
Why?
|
Genotype | 6 | 2016 | 12982 | 0.080 |
Why?
|
Liver | 1 | 2023 | 7531 | 0.070 |
Why?
|
Myocardial Contraction | 3 | 1999 | 1516 | 0.070 |
Why?
|
Nitric Oxide Synthase | 4 | 1999 | 906 | 0.070 |
Why?
|
Intracranial Hemorrhages | 5 | 2015 | 822 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2321 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2013 | 787 | 0.070 |
Why?
|
Niacin | 2 | 2019 | 118 | 0.070 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2009 | 412 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2016 | 2570 | 0.070 |
Why?
|
Fibrin | 1 | 2009 | 507 | 0.070 |
Why?
|
Helminth Proteins | 1 | 2007 | 173 | 0.070 |
Why?
|
Survival Rate | 7 | 2018 | 12710 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1669 | 0.070 |
Why?
|
Drug Dosage Calculations | 2 | 2018 | 117 | 0.070 |
Why?
|
Awareness | 1 | 2010 | 647 | 0.070 |
Why?
|
Life Tables | 1 | 2006 | 365 | 0.060 |
Why?
|
Adenosine Monophosphate | 1 | 2007 | 230 | 0.060 |
Why?
|
Adiponectin | 1 | 2011 | 1113 | 0.060 |
Why?
|
Chemokine CCL2 | 1 | 2007 | 604 | 0.060 |
Why?
|
Triage | 1 | 2012 | 986 | 0.060 |
Why?
|
Exercise Test | 2 | 2011 | 2129 | 0.060 |
Why?
|
Sex Distribution | 3 | 2017 | 2281 | 0.060 |
Why?
|
Thromboxane A2 | 1 | 2004 | 88 | 0.060 |
Why?
|
Circadian Rhythm | 2 | 2013 | 2574 | 0.060 |
Why?
|
Enzyme Inhibitors | 2 | 2014 | 3710 | 0.060 |
Why?
|
Antifibrinolytic Agents | 1 | 2007 | 292 | 0.060 |
Why?
|
Case Management | 1 | 2006 | 272 | 0.060 |
Why?
|
Angiopoietins | 1 | 2024 | 85 | 0.060 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2006 | 361 | 0.060 |
Why?
|
Retrospective Studies | 15 | 2014 | 80575 | 0.060 |
Why?
|
Microfilament Proteins | 1 | 2009 | 1134 | 0.060 |
Why?
|
Algorithms | 3 | 2020 | 14025 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2853 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2023 | 89 | 0.050 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1529 | 0.050 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 1600 | 0.050 |
Why?
|
Subtilisins | 1 | 2022 | 81 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1792 | 0.050 |
Why?
|
Creatine Kinase | 1 | 2004 | 686 | 0.050 |
Why?
|
China | 2 | 2020 | 2348 | 0.050 |
Why?
|
Length of Stay | 2 | 2012 | 6422 | 0.050 |
Why?
|
Neoplasms | 4 | 2019 | 22158 | 0.050 |
Why?
|
Isoenzymes | 2 | 2004 | 1688 | 0.050 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2023 | 197 | 0.050 |
Why?
|
Aging | 1 | 2019 | 8704 | 0.040 |
Why?
|
Women's Health | 1 | 2010 | 2065 | 0.040 |
Why?
|
Phenylbutazone | 1 | 2020 | 7 | 0.040 |
Why?
|
Tolbutamide | 1 | 2020 | 23 | 0.040 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1665 | 0.040 |
Why?
|
Hematocrit | 1 | 2022 | 625 | 0.040 |
Why?
|
Phosphoproteins | 1 | 2009 | 2445 | 0.040 |
Why?
|
Coronary Vessels | 1 | 2011 | 3094 | 0.040 |
Why?
|
Necrosis | 1 | 2004 | 1605 | 0.040 |
Why?
|
Equipment Design | 1 | 2008 | 3510 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5665 | 0.040 |
Why?
|
Age Distribution | 2 | 2017 | 2880 | 0.040 |
Why?
|
Europe | 1 | 2006 | 3420 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14597 | 0.040 |
Why?
|
Adenosine Diphosphate | 2 | 2011 | 422 | 0.040 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2000 | 866 | 0.040 |
Why?
|
Inflammation | 2 | 2012 | 10760 | 0.040 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2016 | 1241 | 0.040 |
Why?
|
Nitric Oxide | 2 | 1999 | 2133 | 0.040 |
Why?
|
Up-Regulation | 3 | 2016 | 4120 | 0.040 |
Why?
|
Oxazoles | 1 | 2020 | 199 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2009 | 5492 | 0.040 |
Why?
|
Comorbidity | 3 | 2011 | 10498 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 2691 | 0.040 |
Why?
|
Smoking | 2 | 2013 | 9051 | 0.040 |
Why?
|
Potassium | 1 | 2022 | 1311 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2019 | 680 | 0.040 |
Why?
|
Lipids | 2 | 2006 | 3341 | 0.040 |
Why?
|
Carbazoles | 1 | 1999 | 220 | 0.040 |
Why?
|
Nitroso Compounds | 1 | 1997 | 71 | 0.040 |
Why?
|
Down-Regulation | 1 | 2024 | 2913 | 0.040 |
Why?
|
Digitalis Glycosides | 1 | 2016 | 47 | 0.030 |
Why?
|
Vascular Patency | 2 | 2010 | 910 | 0.030 |
Why?
|
DNA | 1 | 2010 | 7216 | 0.030 |
Why?
|
HIV Infections | 1 | 2023 | 17346 | 0.030 |
Why?
|
Glycine | 1 | 2020 | 666 | 0.030 |
Why?
|
Pharmacogenetics | 2 | 2010 | 675 | 0.030 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 253 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2017 | 370 | 0.030 |
Why?
|
Rhabdomyolysis | 1 | 2017 | 152 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2017 | 299 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 414 | 0.030 |
Why?
|
Liver Diseases | 2 | 2017 | 1296 | 0.030 |
Why?
|
Long QT Syndrome | 1 | 2000 | 467 | 0.030 |
Why?
|
Disease Management | 2 | 2017 | 2504 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 1997 | 298 | 0.030 |
Why?
|
Government Regulation | 1 | 2020 | 524 | 0.030 |
Why?
|
Diet, Reducing | 1 | 2019 | 485 | 0.030 |
Why?
|
Genetic Variation | 1 | 2010 | 6571 | 0.030 |
Why?
|
Drug Utilization | 2 | 2012 | 1188 | 0.030 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 411 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2017 | 628 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17872 | 0.030 |
Why?
|
Norepinephrine | 1 | 1997 | 897 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 12972 | 0.030 |
Why?
|
Injections, Intravenous | 2 | 2013 | 1379 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 579 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2016 | 490 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18401 | 0.030 |
Why?
|
Body Weight | 2 | 2018 | 4614 | 0.030 |
Why?
|
Area Under Curve | 2 | 2008 | 1633 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2020 | 1299 | 0.030 |
Why?
|
Placebo Effect | 1 | 2017 | 518 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 806 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2016 | 539 | 0.030 |
Why?
|
Myocardium | 2 | 2004 | 4723 | 0.030 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.030 |
Why?
|
Spinal Fractures | 1 | 2019 | 705 | 0.030 |
Why?
|
Graft Occlusion, Vascular | 1 | 2016 | 537 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8632 | 0.030 |
Why?
|
Muscular Diseases | 1 | 2017 | 553 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2395 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 549 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 2017 | 480 | 0.030 |
Why?
|
Pyridostigmine Bromide | 1 | 1992 | 31 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2023 | 0.030 |
Why?
|
Internationality | 1 | 2017 | 1001 | 0.020 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2011 | 69 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6341 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2016 | 1737 | 0.020 |
Why?
|
Long-Term Care | 1 | 2015 | 633 | 0.020 |
Why?
|
Platelet Activating Factor | 1 | 2011 | 143 | 0.020 |
Why?
|
Tachycardia, Ventricular | 1 | 2000 | 1304 | 0.020 |
Why?
|
Hip Fractures | 1 | 2019 | 988 | 0.020 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2016 | 850 | 0.020 |
Why?
|
Databases, Factual | 2 | 2021 | 7954 | 0.020 |
Why?
|
Indoles | 1 | 1999 | 1832 | 0.020 |
Why?
|
Reperfusion | 1 | 2011 | 270 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 598 | 0.020 |
Why?
|
Preventive Health Services | 1 | 2015 | 567 | 0.020 |
Why?
|
Somatostatin | 1 | 1992 | 447 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2642 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2019 | 1943 | 0.020 |
Why?
|
Growth Hormone | 1 | 1992 | 569 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2722 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2011 | 713 | 0.020 |
Why?
|
Biotransformation | 1 | 2009 | 166 | 0.020 |
Why?
|
Microsomes, Liver | 1 | 2009 | 173 | 0.020 |
Why?
|
Plasminogen Activators | 1 | 2009 | 199 | 0.020 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2010 | 344 | 0.020 |
Why?
|
Calcium | 2 | 1999 | 5726 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2605 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1385 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2000 | 9534 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1555 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2018 | 1580 | 0.020 |
Why?
|
Shock, Cardiogenic | 1 | 2013 | 709 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2019 | 2046 | 0.020 |
Why?
|
Enzyme Activation | 3 | 1999 | 3592 | 0.020 |
Why?
|
American Heart Association | 1 | 2011 | 1045 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3572 | 0.020 |
Why?
|
Adolescent | 4 | 2012 | 88305 | 0.020 |
Why?
|
Research | 1 | 2015 | 1977 | 0.020 |
Why?
|
Bone Density | 1 | 2019 | 3551 | 0.020 |
Why?
|
Pancreatitis | 1 | 2013 | 1096 | 0.020 |
Why?
|
Health Status | 1 | 2019 | 4075 | 0.020 |
Why?
|
Health Resources | 1 | 2012 | 935 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1908 | 0.020 |
Why?
|
Medication Adherence | 1 | 2017 | 2176 | 0.020 |
Why?
|
Pyrrolidines | 1 | 2007 | 338 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 4991 | 0.020 |
Why?
|
Electrophysiology | 2 | 2000 | 1262 | 0.020 |
Why?
|
Home Care Services | 1 | 2012 | 648 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1428 | 0.020 |
Why?
|
Alanine | 1 | 2007 | 607 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 883 | 0.010 |
Why?
|
Heart Rate | 1 | 2016 | 4197 | 0.010 |
Why?
|
Probability | 1 | 2010 | 2478 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2010 | 2927 | 0.010 |
Why?
|
Phosphorylation | 2 | 2009 | 8312 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4649 | 0.010 |
Why?
|
Seasons | 1 | 2009 | 1519 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5334 | 0.010 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2013 | 2119 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 3 | 1999 | 8166 | 0.010 |
Why?
|
Heterozygote | 1 | 2008 | 2803 | 0.010 |
Why?
|
Decision Making | 1 | 2015 | 3929 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1471 | 0.010 |
Why?
|
Drug Costs | 1 | 2009 | 1183 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13355 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2011 | 2319 | 0.010 |
Why?
|
Gemfibrozil | 1 | 2000 | 30 | 0.010 |
Why?
|
Rats | 4 | 1999 | 23729 | 0.010 |
Why?
|
Quality Improvement | 1 | 2015 | 3800 | 0.010 |
Why?
|
Young Adult | 3 | 2012 | 59196 | 0.010 |
Why?
|
Nitroarginine | 1 | 1999 | 66 | 0.010 |
Why?
|
Cyclic GMP-Dependent Protein Kinases | 1 | 1999 | 28 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26108 | 0.010 |
Why?
|
Linear Models | 1 | 2009 | 5871 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3243 | 0.010 |
Why?
|
Methylene Blue | 1 | 1999 | 155 | 0.010 |
Why?
|
Tunica Intima | 1 | 2000 | 459 | 0.010 |
Why?
|
Alkaloids | 1 | 1999 | 192 | 0.010 |
Why?
|
Cyclic GMP | 1 | 1999 | 395 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 2007 | 2246 | 0.010 |
Why?
|
Neurons | 1 | 1997 | 9458 | 0.010 |
Why?
|
S-Nitroso-N-Acetylpenicillamine | 1 | 1997 | 23 | 0.010 |
Why?
|
Homocysteine | 1 | 2000 | 638 | 0.010 |
Why?
|
Penicillamine | 1 | 1997 | 60 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1922 | 0.010 |
Why?
|
Ganglia, Sympathetic | 1 | 1997 | 65 | 0.010 |
Why?
|
Cell Size | 1 | 1999 | 624 | 0.010 |
Why?
|
PC12 Cells | 1 | 1997 | 317 | 0.010 |
Why?
|
Electroencephalography | 1 | 2012 | 6224 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2000 | 1370 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2012 | 14665 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9319 | 0.010 |
Why?
|
Enzyme Induction | 1 | 1996 | 451 | 0.010 |
Why?
|
Carotid Arteries | 1 | 2000 | 941 | 0.010 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 1999 | 704 | 0.010 |
Why?
|
Reaction Time | 1 | 2000 | 2080 | 0.010 |
Why?
|
Hormones | 1 | 1997 | 867 | 0.010 |
Why?
|
Coculture Techniques | 1 | 1997 | 1341 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4921 | 0.010 |
Why?
|
Action Potentials | 1 | 2000 | 1834 | 0.010 |
Why?
|
Biological Transport | 1 | 1997 | 2090 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1992 | 866 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15879 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1992 | 2090 | 0.010 |
Why?
|
Animals | 6 | 2000 | 168388 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 1997 | 2229 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1997 | 18962 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2007 | 22124 | 0.010 |
Why?
|
Heart Ventricles | 1 | 1999 | 3816 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1996 | 4432 | 0.000 |
Why?
|
Mutation | 1 | 2008 | 30044 | 0.000 |
Why?
|
Phenotype | 1 | 2000 | 16603 | 0.000 |
Why?
|
Cytokines | 1 | 1996 | 7390 | 0.000 |
Why?
|
Mice | 1 | 2000 | 81474 | 0.000 |
Why?
|